Trials / Completed
CompletedNCT03017690
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 22 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
Conditions
Timeline
- Start date
- 2017-04-12
- Primary completion
- 2018-05-30
- Completion
- 2018-05-30
- First posted
- 2017-01-11
- Last updated
- 2018-12-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03017690. Inclusion in this directory is not an endorsement.